文献速递血液净化与透析肾血管病与高血压

阿哌沙班用于透析合并新发房颤患者的有效性与安全性

Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis.
PubMed 文献 · Am J Kidney Dis · 2025-12-04

该回顾性队列纳入2014至2019年医保覆盖的透析终末期肾病患者,新发房颤后30天内启动阿哌沙班者4010例,未启动任何口服抗凝者59290例。倾向匹配后阿哌沙班组缺血性卒中、血栓栓塞复合终点及全因死亡风险更低,但出血性卒中与临床重要出血风险更高。

要点

  • 透析合并新发房颤患者尽早启动阿哌沙班与缺血性卒中及死亡风险降低相关
  • 阿哌沙班增加出血性卒中与临床重要出血风险,需权衡获益与风险
  • 该研究为观察性设计,残余混杂可能影响因果推断

核心结论

  • 在透析终末期肾病合并新发房颤患者中,与不启动口服抗凝相比,新诊断房颤后30天内启动阿哌沙班与缺血性卒中、血栓栓塞复合终点及全因死亡风险降低相关,但临床重要出血发生率更高。

研究设计与样本

  • 回顾性队列研究,基于2014-2019年医保数据,纳入透析终末期肾病合并新发房颤且近期未使用口服抗凝药的患者共63300例。
  • 30天内启动阿哌沙班者4010例,未启动任何口服抗凝者59290例;倾向匹配后各3985例进行比较,采用Cox比例风险模型并考虑竞争风险。

主要发现

  • 阿哌沙班启动时间中位为房颤诊断后5天(IQR 2-12),使用中位时长59天(IQR 37-135);匹配队列CHA2DS2-VASc中位数为4(IQR 3-5)。
  • 意向性分析中,阿哌沙班组缺血性卒中发生率低25%(HR 0.75;95%CI 0.57-0.97),血栓栓塞事件与心血管死亡复合终点低24%(HR 0.76;95%CI 0.70-0.83),全因死亡HR 0.61(95%CI 0.56-0.67)。
  • 阿哌沙班组出血性卒中发生率高55%(HR 1.55;95%CI 1.03-2.33),临床重要出血发生率高29%(HR 1.29;95%CI 1.14-1.45)。
  • 按治疗分析结果与意向性分析定性一致,但效应幅度总体更大。

临床怎么用

  • 对透析合并新发房颤患者,可与患者共同决策是否启动阿哌沙班,综合评估缺血性卒中与出血风险。
  • 启动阿哌沙班后应关注出血事件,尤其是出血性卒中和需住院的临床重要出血。

局限性

  • 可能存在未观测特征的残余混杂。
  • 竞争风险模型未能完全处理信息性删失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Atrial fibrillation (AF) is common among patients with kidney failure treated with hemodialysis. We studied the outcomes of apixaban initiation compared with no initiation of any oral anticoagulation among patients with hemodialysis-treated kidney failure and newly diagnosed AF. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Medicare-insured patients with hemodialysis-treated kidney failure with newly diagnosed AF and without recent oral anticoagulant (OAC) use (2014-2019). EXPOSURE: Initiation of apixaban treatment versus no OAC initiation within 30 days of an AF diagnosis. OUTCOMES: Thromboembolic and bleeding events and death within 365 days of follow-up. ANALYTICAL APPROACH: Propensity-matched comparison of new apixaban users and OAC nonusers implemented using Cox proportional hazards models while accounting for competing risks. RESULTS: Within 30 days of the new diagnosis of AF among 63,300 previously OAC-naïve patients, 4,010 initiated apixaban and 59,290 did not initiate any OAC. After propensity matching, 3,985 apixaban users were well matched to 3,985 OAC nonusers on all measured characteristics. Median CHA2DS2-VASc, a multidimensional stroke risk score, was 4 (interquartile range [IQR], 3-5). Apixaban was initiated a median of 5 (IQR, 2-12) days after AF and used for a median of 59 (IQR, 37-135) days. In intention-to-treat analyses, rates of ischemic stroke were 25% lower (HR, 0.75; 95% CI, 0.57-0.97) and those of a composite outcome of thromboembolic events and cardiovascular death were 24% lower (HR, 0.76; 95% CI, 0.70-0.83) among apixaban users. Conversely, apixaban users had a 55% higher rate of hemorrhagic stroke (HR, 1.55; 95% CI, 1.03-2.33) and a 29% increased rate of clinically important bleeding (HR, 1.29; 95% CI, 1.14-1.45). The HR for all-cause mortality was 0.61 (95% CI, 0.56-0.67). Results from as-treated analyses were qualitatively consistent with intent-to-treat analyses but generally larger in magnitude. LIMITATIONS: Potential for residual confounding from unobserved characteristics or informative censoring unaccounted for by competing risk models. CONCLUSIONS: Among patients with hemodialysis-treated kidney failure, compared with no anticoagulation, initiation of apixaban soon after newly diagnosed AF was associated with lower risks of ischemic stroke, a composite thromboembolic end point, and all-cause mortality but higher rates of clinically meaningful bleeding. PLAIN-LANGUAGE SUMMARY: In this study of existing data of patients with kidney failure receiving dialysis who were newly diagnosed with atrial fibrillation, the most common heart rhythm disorder, we found that initiating a newer blood thinner, apixaban, was associated with fewer strokes, other clotting-related cardiovascular events, and deaths compared with what was observed in patients who did not initiate any blood-thinner treatment after their atrial fibrillation diagnosis. However, patients initiating apixaban did have higher rates of bleeding events that required hospitalization or, rarely, led to death. The information presented in this study can be used to inform shared decision-making between patients and their physicians.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Winkelmayer WC, Erickson KF, Khairallah P, et al. Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis. Am J Kidney Dis. 2025. PMID: 41352721. doi:10.1053/j.ajkd.2025.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。